Market Cap 153.80B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.43
Forward PE 9.15
Profit Margin 12.42%
Debt to Equity Ratio 0.66
Volume 43,760,600
Avg Vol 49,896,098
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 95%
Beta 0.47
Analysts Sell
Price Target $28.43

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
NasdaqKnight
NasdaqKnight Feb. 11 at 11:13 AM
$PFE | Obesity program raises more questions than confidence If this is helpful to you, tap @NasdaqKnight Hard to ignore the disconnect in Pfizer’s dosing model. 9.6 mg monthly ≈ 2.4 mg weekly with sharp PK peaks — yet little discussion around receptor saturation, mechanism limits, or AE escalation. That’s a big red flag for a company of this caliber. For context: Metsera capped weekly dosing at 1.6 mg in Phase 1 and didn’t advance it — likely due to tolerability. Chasing deeper weight loss often comes at the cost of patient adherence. nausea/vomiting spikes, that’s not a commercial win. Early signals don’t inspire confidence: • Questionable dose strategy • High emesis rates emerging in amylin programs (Phase 1 MAD already elevated) • Risk that efficacy is being “bought” with poor tolerability Meanwhile, $NVO dodges a bullet and $LLY openly signals confidence, letting competitors “fight for it.” In obesity, tolerability is the moat — not headline % weight loss.
0 · Reply
Paulzk
Paulzk Feb. 11 at 11:13 AM
$PFE Good article https://finance.yahoo.com/news/pfizer-q4-earnings-call-highlights-060805182.html
0 · Reply
roselynjasiah59
roselynjasiah59 Feb. 11 at 11:10 AM
0 · Reply
gumby2196
gumby2196 Feb. 11 at 9:59 AM
$PFE we are attempting a range break out here. Technically, the box can be green but we looked below so I still have it as pink. Typically, I look for look above that back tests before I turn range back into support.
0 · Reply
roselynjasiah59
roselynjasiah59 Feb. 11 at 9:58 AM
0 · Reply
Tom2424
Tom2424 Feb. 11 at 9:44 AM
$VXRT $PFE $SNY $MRNA FDA RTF for Moderna flu confirms systemic mRNA cannot overcome 'Antigenic Shunt'. Mucosal IgA is the new benchmark. 🧬 In 2024, Lutnick (White House advisor/former Cantor CEO) pushed "2 Billion doses" while Oppenheimer ATMs and indirect institutional backdoors capped $VXRT & $DVAX price discovery. Massive conflict? Sanofi’s Feb 10 $DVAX capture is a strategic backdoor to VAAST tech. Probable SEC TCRs are now surfacing regarding these conflicts & suppressed N=5000 trial metrics (8% Delta). The "Sentinel Ultimatum" is ticking. ⏳ Bourla (Pfizer) is cornered; mRNA-1010 failure leaves $PFE with no respiratory moat. He has 2-4 weeks to intercept $VXRT before N=400 data makes the price prohibitive & Sanofi integrates. Hostile bid incoming to block the French capture of US-funded IP? The biology of the oral pill is winning. #VAAST #Vaxart #Pfizer #Sanofi #Lutnick #FDA #StockMarket #BioTech #Trump #Sentinel
1 · Reply
framus_morrigan
framus_morrigan Feb. 11 at 9:07 AM
$PFE Early QUARTERLY candles chart to show how this is going after that wedge breakout. "IF" this breaks 28.46 level then more room to go ( see fibo levels ). GLTA
0 · Reply
Patoun
Patoun Feb. 11 at 8:55 AM
$BMEA I am accumulating on this stock without thinking, at least up to $5... target of $30 within a maximum of 2 years and I think it will be much sooner. Why ? The Patent Cliffs: Semaglutide (Ozempic) will begin facing generic competition by the early 2030s. For giants like Novo Nordisk or Eli Lilly, a classic Lifecycle Management (LCM) strategy involves developing a proprietary Fixed-Dose Combination (FDC). A more than realistic scenario is that either $NVO (Or $LLY or $PFE ) will acquire Biomea to launch a single pill combining generic semaglutide + icovamenib. Result: They secure a fresh 15-to-20-year patent exclusivity window for a product that is significantly more effective than the generic alone. The GLP-1 market is becoming saturated (Lilly, Novo, Roche, Viking, Amgen). To win, simply inducing weight loss is no longer sufficient. Goal is now to achieve better weight loss (improved quality/body composition) and sustainable results, that is : a "disease-modifying" effect.
0 · Reply
DrRobertoMorenoMD
DrRobertoMorenoMD Feb. 11 at 8:27 AM
In $QNCX @ 0.94 $PFE $MRNA
0 · Reply
LadsAndGents
LadsAndGents Feb. 11 at 6:27 AM
$PFE moves so slow.. only asking for mid 30s by EOY $SPY
0 · Reply
Latest News on PFE
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 3:00 PM EST - 7 days ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript


Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 2:02 PM EST - 7 days ago

Pfizer: Messy Q4 Earnings Mask An Improving Business


Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 7 days ago

Silver Surges Over 15%; Pfizer Earnings Top Views


Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 7 days ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand


Pfizer: Buyer Beware, The Risk Outweighs The Reward

Jan 30, 2026, 10:31 AM EST - 11 days ago

Pfizer: Buyer Beware, The Risk Outweighs The Reward


Why Dividend Stocks Are Essential For What Comes Next

Jan 30, 2026, 7:30 AM EST - 11 days ago

Why Dividend Stocks Are Essential For What Comes Next

AM CAG EPD ET KMI LLY MPLX


Pfizer: A High-Yield Pharma At A Turning Point

Jan 29, 2026, 9:00 AM EST - 12 days ago

Pfizer: A High-Yield Pharma At A Turning Point


Pfizer vs. Merck Stock And JNJ

Jan 27, 2026, 7:40 AM EST - 14 days ago

Pfizer vs. Merck Stock And JNJ


Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

Jan 23, 2026, 10:33 AM EST - 18 days ago

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)


Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Jan 20, 2026, 12:34 PM EST - 21 days ago

Pfizer CEO Albert Bourla: U.S. drug prices are coming down


Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits

Jan 20, 2026, 2:19 AM EST - 22 days ago

Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits


MoneyShow's Best Investment Ideas For 2026: Part 7

Jan 19, 2026, 2:20 PM EST - 22 days ago

MoneyShow's Best Investment Ideas For 2026: Part 7

PLD PLG PM QUIK RCAT


Pfizer: Rebound Has Just Started

Jan 16, 2026, 1:08 PM EST - 25 days ago

Pfizer: Rebound Has Just Started


Pfizer: The Most Intriguing Value Play Of 2026

Jan 15, 2026, 8:58 AM EST - 26 days ago

Pfizer: The Most Intriguing Value Play Of 2026


Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Jan 13, 2026, 6:11 AM EST - 4 weeks ago

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy


NasdaqKnight
NasdaqKnight Feb. 11 at 11:13 AM
$PFE | Obesity program raises more questions than confidence If this is helpful to you, tap @NasdaqKnight Hard to ignore the disconnect in Pfizer’s dosing model. 9.6 mg monthly ≈ 2.4 mg weekly with sharp PK peaks — yet little discussion around receptor saturation, mechanism limits, or AE escalation. That’s a big red flag for a company of this caliber. For context: Metsera capped weekly dosing at 1.6 mg in Phase 1 and didn’t advance it — likely due to tolerability. Chasing deeper weight loss often comes at the cost of patient adherence. nausea/vomiting spikes, that’s not a commercial win. Early signals don’t inspire confidence: • Questionable dose strategy • High emesis rates emerging in amylin programs (Phase 1 MAD already elevated) • Risk that efficacy is being “bought” with poor tolerability Meanwhile, $NVO dodges a bullet and $LLY openly signals confidence, letting competitors “fight for it.” In obesity, tolerability is the moat — not headline % weight loss.
0 · Reply
Paulzk
Paulzk Feb. 11 at 11:13 AM
$PFE Good article https://finance.yahoo.com/news/pfizer-q4-earnings-call-highlights-060805182.html
0 · Reply
roselynjasiah59
roselynjasiah59 Feb. 11 at 11:10 AM
0 · Reply
gumby2196
gumby2196 Feb. 11 at 9:59 AM
$PFE we are attempting a range break out here. Technically, the box can be green but we looked below so I still have it as pink. Typically, I look for look above that back tests before I turn range back into support.
0 · Reply
roselynjasiah59
roselynjasiah59 Feb. 11 at 9:58 AM
0 · Reply
Tom2424
Tom2424 Feb. 11 at 9:44 AM
$VXRT $PFE $SNY $MRNA FDA RTF for Moderna flu confirms systemic mRNA cannot overcome 'Antigenic Shunt'. Mucosal IgA is the new benchmark. 🧬 In 2024, Lutnick (White House advisor/former Cantor CEO) pushed "2 Billion doses" while Oppenheimer ATMs and indirect institutional backdoors capped $VXRT & $DVAX price discovery. Massive conflict? Sanofi’s Feb 10 $DVAX capture is a strategic backdoor to VAAST tech. Probable SEC TCRs are now surfacing regarding these conflicts & suppressed N=5000 trial metrics (8% Delta). The "Sentinel Ultimatum" is ticking. ⏳ Bourla (Pfizer) is cornered; mRNA-1010 failure leaves $PFE with no respiratory moat. He has 2-4 weeks to intercept $VXRT before N=400 data makes the price prohibitive & Sanofi integrates. Hostile bid incoming to block the French capture of US-funded IP? The biology of the oral pill is winning. #VAAST #Vaxart #Pfizer #Sanofi #Lutnick #FDA #StockMarket #BioTech #Trump #Sentinel
1 · Reply
framus_morrigan
framus_morrigan Feb. 11 at 9:07 AM
$PFE Early QUARTERLY candles chart to show how this is going after that wedge breakout. "IF" this breaks 28.46 level then more room to go ( see fibo levels ). GLTA
0 · Reply
Patoun
Patoun Feb. 11 at 8:55 AM
$BMEA I am accumulating on this stock without thinking, at least up to $5... target of $30 within a maximum of 2 years and I think it will be much sooner. Why ? The Patent Cliffs: Semaglutide (Ozempic) will begin facing generic competition by the early 2030s. For giants like Novo Nordisk or Eli Lilly, a classic Lifecycle Management (LCM) strategy involves developing a proprietary Fixed-Dose Combination (FDC). A more than realistic scenario is that either $NVO (Or $LLY or $PFE ) will acquire Biomea to launch a single pill combining generic semaglutide + icovamenib. Result: They secure a fresh 15-to-20-year patent exclusivity window for a product that is significantly more effective than the generic alone. The GLP-1 market is becoming saturated (Lilly, Novo, Roche, Viking, Amgen). To win, simply inducing weight loss is no longer sufficient. Goal is now to achieve better weight loss (improved quality/body composition) and sustainable results, that is : a "disease-modifying" effect.
0 · Reply
DrRobertoMorenoMD
DrRobertoMorenoMD Feb. 11 at 8:27 AM
In $QNCX @ 0.94 $PFE $MRNA
0 · Reply
LadsAndGents
LadsAndGents Feb. 11 at 6:27 AM
$PFE moves so slow.. only asking for mid 30s by EOY $SPY
0 · Reply
robolo
robolo Feb. 11 at 6:20 AM
$PFE Ready for a big move? Regardless of the significant premiums paid, Bourla has been steadily repositioning the company away from its image as a COVID-driven business.
0 · Reply
Blizzy
Blizzy Feb. 11 at 5:43 AM
$PFE is it breaking $28 -> $30+ technical gap or yet another fakeout breakdown? Buying $30 Jan 27’ call options (..again 🙄😤) if it breaks $28 and holds with volume 🎱⏳🤞🏼🤷🏻‍♂️📉📈
0 · Reply
RunnerSignals
RunnerSignals Feb. 11 at 4:38 AM
$AA $AG $PFE $SMCI $U lighting up with unusual options bets. smart money positioning before the move? Full breakdown inside https://stocksrunner.com/news/2026-02-10-unusual-stock-options-analysis
0 · Reply
taxplanr
taxplanr Feb. 11 at 3:12 AM
What are the chances he didn't have the chicken pox vaccine also? $BNTX $MRNA $PFE https://trendingpoliticsnews.com/star-actor-dies-suddenly-at-33-jrupp/?utm_source=DS21
0 · Reply
doubleuptwice
doubleuptwice Feb. 10 at 11:56 PM
$PFE will have a read on the chart by Thursday/friday
1 · Reply
Tiger65
Tiger65 Feb. 10 at 11:04 PM
$PFE come on Pfizer, give us another candy tomorrow. Let’s finally return to that longterm uptrend, please. We all want to reconcile with you ✌️☮️🎸.
0 · Reply
Willieberich
Willieberich Feb. 10 at 11:00 PM
$PFE remember to say this to yourself when you invest in a company .stop trying to get rich fast .good luck people .in an uptrend since April 8 th .I bought in the 24 level doing great ...
1 · Reply
EmbraceVolatility
EmbraceVolatility Feb. 10 at 10:43 PM
$PFE Be careful selling calls. This can make a GM type revaluation move.
1 · Reply
Pep1234
Pep1234 Feb. 10 at 10:23 PM
$PFE was that the break we've been waiting above $27.37? 🤔 A call will do... as long as it stays closing above that figure.
0 · Reply
DocPharm
DocPharm Feb. 10 at 9:07 PM
$PFE curling
0 · Reply
RocroBio
RocroBio Feb. 10 at 8:39 PM
0 · Reply
RocroBio
RocroBio Feb. 10 at 8:38 PM
$PFE 👍🏼
0 · Reply